Adams Faces Another Mucinex Challenge, Prepares For Product Launches
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season
You may also be interested in...
Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin
Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM
Reckitt’s Revenues Soar On Strength Of Adams Brands, Product Innovations
Reckitt-Benckiser's revenues soared 13 percent in fiscal 2008 as health care and personal product sales grew more than twice as fast as its other segments - a trend the firm expects to continue despite private label competition and the global economic slump
Reckitt Raises Guidance On Adams Performance, Marketing Momentum
Reckitt Benckiser raises its 2008 sales targets based on the performance of brands added with its acquisition of Adams Respiratory Therapeutics early this year and heavy marketing investment in its latest quarter